© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 16, 1211-1220,
August 21, 2002
© 2002 Oxford University Press
ARTICLE |
Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy
For the AranespTM 980297 Study Group
Affiliations of authors: J. Vansteenkiste, University Hospital Gasthuisberg, Leuven, Belgium; R. Pirker, Universitätsklinik für Innere Medizin 1, Vienna, Austria; B. Massuti, Hospital General de Alicante, Alicante, Spain; F. Barata, Centro Hospitalar de Coimbra, Coimbra, Portugal; A. Font, Hospital Germans Trias I Pujol, Badalona, Spain; M. Fiegl, Innsbruck University Hospital, Innsbruck, Austria; S. Siena, Ospedale Niguarda Cà Granda, Milan, Italy; J. Gateley, D. Tomita, A. B. Colowick, Amgen Inc., Thousand Oaks, CA; J. Musil, University Hospital Bulovka, Prague, Czech Republic.
Correspondence to: Johan Vansteenkiste, M.D., Ph.D., Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Leuven, Belgium (e-mail: johan.vansteenkiste{at}uz.kuleuven.ac.be).
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (AranespTM) is an erythropoiesis-stimulating glycoprotein that has been shown, in dose-finding studies, to be safe and clinically active when administered to patients with cancer every 1, 2, or 3 weeks. This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy. Methods: In this multicenter, double-blind, placebo-controlled study, 320 anemic patients (hemoglobin 
11.0 g/dL) were randomly assigned to receive darbepoetin alfa or placebo injections weekly for 12 weeks. The 297 patients who completed at least the first 28 days of study were assessed for red blood cell transfusions, the primary endpoint. Patients were also assessed for hemoglobin concentration (i.e., hematopoietic response), adverse events, antibody formation to darbepoetin alfa, hospitalizations, Functional Assessment of Cancer Therapy (FACT)–Fatigue score, and disease outcome. Efficacy endpoints were assessed using Kaplan–Meier analyses, Cox proportional hazards analyses, and chi-square tests where appropriate. All statistical tests were two-sided. Results: Patients receiving darbepoetin alfa required fewer transfusions (27% versus 52%; mean difference = 25%; 95% confidence interval [CI] = 14% to 36%; P<.001), required fewer units of blood (0.67 versus 1.92; mean difference = 1.25, 95% CI = 0.65 to 1.84; P<.001), had more hematopoietic responses (66% versus 24%; mean difference = 42%; 95% CI = 31% to 53%; P<.001), and had better improvement in FACT–Fatigue scores (56% versus 44% overall improvement; 32% versus 19% with 
25% improvement; mean difference = 13%; 95% CI = 2% to 23%, P = .019) than patients receiving placebo. Patients receiving darbepoetin alfa did not appear to have any untoward effect in disease outcome and did not develop antibodies to the drug. Adverse events were similar between the groups. Conclusions: Patients with chemotherapy-associated anemia can safely and effectively be treated with weekly darbepoetin alfa therapy. Darbepoetin alfa decreased blood transfusion requirements, increased hemoglobin concentration, and decreased fatigue. Although no conclusions can be drawn about survival from this study, the potential salutary effect on disease outcome warrants further investigation in a prospectively designed study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Minton, A. Richardson, M. Sharpe, M. Hotopf, and P. Stone A Systematic Review and Meta-Analysis of the Pharmacological Treatment of Cancer-Related Fatigue J Natl Cancer Inst, August 20, 2008; 100(16): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gordon, G. Nichols, A. Ben-Jacob, D. Tomita, T. Lillie, and C. Miller Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study Oncologist, June 1, 2008; 13(6): 715 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pirker, R. A. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, and J. F. Vansteenkiste Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide J. Clin. Oncol., May 10, 2008; 26(14): 2342 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Spaepen, N. Demarteau, S. Van Belle, and L. Annemans Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals Oncologist, May 1, 2008; 13(5): 596 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gascon Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Oncologist, May 1, 2008; 13(suppl_3): 4 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dicato Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Oncologist, May 1, 2008; 13(suppl_3): 11 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bastit, A. Vandebroek, S. Altintas, B. Gaede, T. Pinter, T. S. Suto, T. W. Mossman, K. E. Smith, and J. F. Vansteenkiste Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia J. Clin. Oncol., April 1, 2008; 26(10): 1611 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pedrazzoli, A. Farris, S. Del Prete, F. Del Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, et al. Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa J. Clin. Oncol., April 1, 2008; 26(10): 1619 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aapro, R. C. Leonard, A. Barnadas, M. Marangolo, M. Untch, N. Malamos, J. Mayordomo, D. Reichert, J. L. Pedrini, L. Ukarma, et al. Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer--Anemia and the Value of Erythropoietin (BRAVE) Study J. Clin. Oncol., February 1, 2008; 26(4): 592 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al. Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update J. Clin. Oncol., January 1, 2008; 26(1): 132 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update Blood, January 1, 2008; 111(1): 25 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, D. Tomita, G. Rossi, T. Rearden, and J. Glaspy A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia Oncologist, October 1, 2007; 12(10): 1253 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Lattanzi and F. R. Khuri Erythropoietins in Oncology N. Engl. J. Med., September 20, 2007; 357(12): 1262 - 1263. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Blau Erythropoietin in Cancer: Presumption of Innocence? Stem Cells, August 1, 2007; 25(8): 2094 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial Oncologist, June 1, 2007; 12(6): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Steinmetz, M. Hellmich, M. Neise, A. Aldaud, C. Lerchenmuller, A. Tsamaloukas, F. Fandel, C. Weiligmann, U. Totzke, and S. Schmitz Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors Oncologist, June 1, 2007; 12(6): 748 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boccia, T. Lillie, D. Tomita, and L. Balducci The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia Oncologist, May 1, 2007; 12(5): 584 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow Pharmacologic Treatment of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Crawford Erythropoietin: High Profile, High Scrutiny J. Clin. Oncol., March 20, 2007; 25(9): 1021 - 1023. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Schwartz Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Reeder Anemia in cancer and critical care patients: Pharmacoeconomic considerations Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S22 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Shammo and F. M. Stewart Hematopoietic growth factors ASH Self-Assessment Program, January 1, 2007; 2007(1): 45 - 60. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cremieux, F. Vekeman, and P. Lefebvre Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 165 - 178. [Abstract] [PDF]
|
|
|
|
|
|
J. Glaspy, S. Vadhan-Raj, R. Patel, L. Bosserman, E. Hu, R. E. Lloyd, R. V. Boccia, D. Tomita, and G. Rossi Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial J. Clin. Oncol., May 20, 2006; 24(15): 2290 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Boccia, I. A. Malik, V. Raja, S. Kahanic, R. Liu, T. Lillie, D. Tomita, B. Clowney, and P. Silberstein Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist, April 1, 2006; 11(4): 409 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Steensma, R. Molina, J. A. Sloan, D. A. Nikcevich, P. L. Schaefer, K. M. Rowland Jr, T. Dentchev, P. J. Novotny, L. K. Tschetter, S. R. Alberts, et al. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1079 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J Cersosimo and D. R Jacobson Epoetin Alfa Versus Darbepoetin Alfa in Chemotherapy-Related Anemia Ann. Pharmacother., January 1, 2006; 40(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann. Onc., December 1, 2005; 16(12): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Burstein, L. M. Parker, A. Keshaviah, J. Doherty, A. H. Partridge, L. Schapira, P. D. Ryan, J. Younger, L. N. Harris, B. Moy, et al. Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy J. Clin. Oncol., November 20, 2005; 23(33): 8340 - 8347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hedenus, J. Vansteenkiste, D. Kotasek, M. Austin, and R. G. Amado Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials J. Clin. Oncol., October 1, 2005; 23(28): 6941 - 6948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Engert Recombinant human erythropoietin in oncology: current status and further developments Ann. Onc., October 1, 2005; 16(10): 1584 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waltzman, C. Croot, G. R. Justice, M. R. Fesen, V. Charu, and D. Williams Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 {micro}g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, September 1, 2005; 10(8): 642 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Justice, J. F. Kessler, J. Jadeja, L. Campos, J. Weick, C.-F. Chen, A. C. Heatherington, and R. G. Amado A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia Ann. Onc., July 1, 2005; 16(7): 1192 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Duh, P. Lefebvre, J. Fastenau, C. T. Piech, and R. J. Waltzman Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve Oncologist, June 1, 2005; 10(6): 438 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Catala, D. A. Bryce, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM) Ann. Onc., May 1, 2005; 16(5): 825 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Leonard, M. Untch, and F. Von Koch Management of anaemia in patients with breast cancer: role of epoetin Ann. Onc., May 1, 2005; 16(5): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Herrington, S. L. Davidson, D. K. Tomita, L. Green, R. E. Smith, and R. V. Boccia Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Schwartzberg, L. K. Yee, F. M. Senecal, V. Charu, D. Tomita, J. Wallace, and G. Rossi A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer Oncologist, November 1, 2004; 9(6): 696 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer Ann. Thorac. Surg., September 1, 2004; 78(3): 1037 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Patton, T. Reeves, and J. Wallace Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice Oncologist, July 1, 2004; 9(4): 451 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, J. Kallich, A. McDermott, and X. Xu The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials Ann. Onc., June 1, 2004; 15(6): 979 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease DTB, March 1, 2004; 42(3): 21 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Kolesar, B. A Duren, and B. G Baranski Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders Journal of Oncology Pharmacy Practice, March 1, 2004; 10(1): 1 - 6. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Brugnara Iron Deficiency and Erythropoiesis: New Diagnostic Approaches Clin. Chem., October 1, 2003; 49(10): 1573 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Rizzo, D. Cella, and J. Seidenfeld In Reply: J. Clin. Oncol., June 1, 2003; 21(11): 2224 - 2225. [Full Text] [PDF]
|
|
|
|
|
|
M. VanAudenrode Re: Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy J Natl Cancer Inst, May 21, 2003; 95(10): 761 - 762. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Vansteenkiste and A. B. Colowick RESPONSE: Re: Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy J Natl Cancer Inst, May 21, 2003; 95(10): 762 - 763. [Full Text] [PDF]
|
|
|
|
|
|
D. Cella, D. Dobrez, and J. Glaspy Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann. Onc., April 1, 2003; 14(4): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Varricchio and J. A. Sloan The Need for and Characteristics of Randomized, Phase III Trials to Evaluate Symptom Management in Patients With Cancer J Natl Cancer Inst, August 21, 2002; 94(16): 1184 - 1185. [Full Text] [PDF]
|
|